drugset / Trial / NCT03568461

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

NCT03568461

Phase 2 Completed 98 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.

Timeline

Start
2018-11-12
Primary completion
2020-11-24
Completion
2025-05-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tisagenlecleucel Cell therapy 6e+07 cells
Subject Tisagenlecleucel Cell therapy 6e+08 cells

Indications